US FDA imposes partial clinical hold on Biohaven epilepsy trials
Biohaven said the U.S. FDA imposed a partial clinical hold, pausing new patient enrollment in its experimental epilepsy drug trials after rodent findings. The company’s shares fell more than 13% in premarket trading.
S. FDA imposed a partial clinical hold on trials of its experimental epilepsy drug after rodent findings, pausing new patient enrollment. The company said the move sent its shares down more than 13% in premarket trading.